ROVI: AGREEMENT WITH FDA TO INITIATE CLINICAL TRIAL OF A NEW THREE-MONTHLY FORMULATION OF LETROZOLE ISM (ANÁLISIS BANCO SABADELL)
The company has just announced that after several talks with the FDA, it has decided to commence the clinical development of a new three-monthly formulation (Letrozol LEBE) vs. the annual formulation initially expected of Letrozol ISM (long-acting injectable for hormone-sensitive breast cancer, 18% T.P.) vs. the daily administration of oral doses of Femara.Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.